• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    PURPOSE: Provided are a pharmaceutical composition containing a quinolinone derivative, which is useful as an anti-allergy agent, and a production method thereof. CONSTITUTION: A quinolinone derivative pharmaceutical composition comprises a quinolinone derivative represented by the structural formula (I): wherein the quinolinone derivative is in the form of particles, which have an average particle diameter of 0.5 to 10 mu m and such a particle size distribution that particles having a particle diameter of 15 mu m or less account for 90% or more of the totality of the particles, and also have a fusion enthalpy of 30 J/g or more, and the surface of the particles are coated with a water-soluble composition containing a water-soluble polymer.
    公开号:KR20020096891A
    申请号:KR1020020031925
    申请日:2002-06-07
    公开日:2002-12-31
    发明作者:구보타류지；아라야히로시；오바타고키；기무라노부유키；후쿠이히로유키；다카가키히데쓰구
    申请人:다이니혼 잉키 가가쿠 고교 가부시키가이샤；
    IPC主号:
    专利说明:

    Quinolinone derivative pharmaceutical composition and its manufacturing method {QUINOLINONE DERIVATIVE PHARMACEUTICAL COMPOSITION AND PRODUCTION METHOD THEREFOR}
    [10] The present invention relates to a pharmaceutical composition containing a quinolinone derivative useful as an antiallergic agent and a method for producing the same.
    [11] Structural Formula (I)
    [12]
    [13] The quinolinone derivative represented by is a compound disclosed in Japanese Patent Application Laid-Open No. 9-255659 (corresponding to U.S. Patent No. 5,942,521), which is low in toxicity to living organisms, immediate asthma, delayed asthma, Bronchial asthma, asthma, irritable pneumonia, atopic dermatitis, allergic contact dermatitis, gallbladder, eczema, allergic conjunctivitis, allergic rhinitis, hay fever, food allergy, allergic gastroenteritis, allergic colitis, drug allergy It is useful as an anti-allergic agent which shows an effect to immediate allergic disease and delayed allergic disease, especially autoimmune disease.
    [14] However, since the quinolinone derivative is a poorly water-soluble drug, the dissolution rate in the digestive tract during oral administration is not necessarily sufficient as a pharmaceutical preparation prepared by the method described in the above publication, and the absorption rate and absorption rate may vary. There was a possibility. For this reason, the development of the pharmaceutical composition which improved the elution rate of the quinolinone derivative in the digestive tract and improved water absorption was calculated | required.
    [15] On the other hand, Japanese Patent Application Laid-Open No. 11-255649 discloses four types of crystal polymorphs, α type, β type, γ type, and δ type, among which the quinolinone derivative is present. Among them, β type and γ It is described that the type crystal is superior in bioabsorbability as compared to the α type crystal. This publication also discloses that the particles obtained by crushing each crystalline form of the quinolinone derivative for about 10 minutes using an automatic agate mortar have improved bioabsorbability compared to before grinding. However, when the quinolinone derivative is pulverized by this method, there is a problem that the crystallinity of the quinolinone derivative crystal is lowered, and as a result, the physicochemical stability of the obtained quinolinone derivative is lowered.
    [16] The problem to be solved by the present invention is to provide a quinolinone derivative pharmaceutical composition and a method for preparing the quinolinone derivative which can quickly elute the active ingredient in the digestive tract, and excellent storage stability.
    [1] 1 is a powder X-ray diffraction diagram before and after grinding of a quinolinone derivative.
    [2] FIG. 2 is a graph showing the relationship between dissolution time and dissolution rate before and after grinding of a quinolinone derivative.
    [3] 3 is a graph showing the relationship between dissolution time and dissolution rate according to the type of water-soluble polymer coated with a quinolinone derivative.
    [4] 4 is a graph showing the relationship between the addition rate of hydroxypropyl cellulose to coat the quinolinone derivative and the disintegration time of the quinolinone derivative pharmaceutical composition.
    [5] 5 is a graph showing the relationship between the dissolution rate and dissolution time of a quinolinone derivative pharmaceutical composition in which the addition rate of hydroxypropyl cellulose coating the quinolinone derivative is changed.
    [6] 6 is a graph showing the relationship between the type of disintegrant added to the quinolinone derivative pharmaceutical composition and the disintegration time of the quinolinone derivative pharmaceutical composition.
    [7] 7 is a graph showing the relationship between the types of disintegrants added to the quinolinone derivative pharmaceutical composition and the elution time and dissolution rate of the quinolinone derivative pharmaceutical composition.
    [8] 8 is a graph showing the relationship between dissolution time and dissolution rate of a quinolinone derivative pharmaceutical composition to which Ac-Di-Sol was added as a disintegrating agent.
    [9] 9 is a graph showing the relationship between the dissolution time and the dissolution rate of the quinolinone derivative pharmaceutical composition coated with a water-soluble polymer and a surfactant.
    [17] The present inventors have intensively studied to achieve the above object, and as a result, the quinolinone derivative particles have an average particle diameter of 0.5 to 10 µm and a particle diameter of 15 µm or less while maintaining the enthalpy of fusion at a high level. By pulverizing into particles having a particle size distribution with a ratio of 90% or more and coating the particles with a water-soluble composition containing a water-soluble polymer, the dissolution rate in the digestive tract is improved and long-term storage stability is improved. It has been found that the present invention has been completed.
    [18] That is, the present invention, in order to solve the above problems, structural formula (I)
    [19]
    [20] A pharmaceutical composition containing a quinolinone derivative represented by the above, wherein the quinolinone derivative has an average particle diameter of 0.5 to 10 µm and a particle size distribution in which a proportion of particles having a particle diameter of 15 µm or less occupies 90% or more. Moreover, it is the particle | grains whose enthalpy of fusion is 3OJ / g or more, The surface of the said particle | grain is covered with the water-soluble composition containing water-soluble polymer, The pharmaceutical composition of quinolinone derivatives provided is provided.
    [21] Moreover, in order to solve the said subject, the said quinolinone derivative represented by said structural formula (I) has an average particle diameter of 0.5-10 micrometers, and the ratio of the particle | grains whose particle diameter is 15 micrometers or less occupies 9O% or more. And a first step of pulverizing into particles having a particle size distribution and having a enthalpy of fusion of 30 J / g or more, and a second step of coating the particles obtained in the first step with a water-soluble composition containing a water-soluble polymer. It provides a method for producing a quinolinone derivative pharmaceutical composition.
    [22] The pharmaceutical composition of the present invention can quickly elute the quinolinone derivative represented by the above formula (I) in the digestive tract, and also has excellent storage stability, so that immediate asthma, delayed asthma, bronchial asthma, pediatric asthma, Irritable pneumonia, atopic dermatitis, allergic contact dermatitis, gallbladder, eczema, allergic rhinitis, hay fever, food allergy, allergic gastroenteritis, allergic colitis, drug allergy, autoimmune diseases, etc., in particular, immediate allergic diseases and It is useful as a preparation of anti-allergic agents which have an effect on delayed allergic diseases.
    [23] In addition, Japanese Patent Laid-Open No. 9-255659 and U.S. Patent No. 5,942,521 are incorporated herein by reference. (Japanese Unexamined Patent Application, First Publication No Hei 9-255659and U.S. Patent No. 5,942,521 are incorporated herein by reference.)
    [24] In the present invention, "the quinolinone derivative has an average particle diameter of 0.5 to 10 mu m, and has a particle size distribution in which the proportion of particles having a particle diameter of 15 mu m or less occupies 90% or more. The proportion of particles having an aerodynamic mean diameter of 0.5 to 10 µm and an aerodynamic diameter of 15 µm or less in the volume-based distribution obtained when the particle size distribution is measured by an aerodynamic time-based dry particle size distribution instrument (AEROSIZER). This means that the particle size distribution occupies 90% or more.
    [25] The quinolinone derivative used in the present invention is not particularly limited in terms of its crystalline form. However, in order for the pharmaceutical composition of the present invention to have better absorption into the living body and stability, the quinolinone derivative is β- or γ-type. The crystal polymorph can be specified by powder X-ray diffraction measurement, differential scanning calorimetry (DSC), or the like.
    [26] The quinolinone derivatives used in the present invention are particles having an average particle diameter of 0.5 to 10 µm and preferably 1 to 5 µm. If the average particle diameter is less than 0.5 μm, the physicochemical stability of the quinolinone derivatives is significantly lowered. If the average particle diameter is larger than 10 μm, the quinolinone derivatives are difficult to elute rapidly in vivo.
    [27] In addition, the quinolinone derivative used in the present invention has a particle size distribution in which the proportion of particles having a particle size of 15 μm or less occupies 90% or more, and preferably 10 μm or less. When the proportion of particles having a particle size larger than 15 µm is contained in excess of 10%, the quinolinone derivatives are difficult to elute rapidly in vivo.
    [28] In addition, the quinolinone derivative used in the present invention has a fusion enthalpy (ΔH) of 30 J / g or more, preferably 35 J / g or more. If the enthalpy of fusion is less than 30 J / g, the physicochemical stability of the quinolinone derivatives is significantly lowered. Herein, the enthalpy of fusion in the present invention is a value obtained from an endothermic peak due to melting of a quinolinone derivative crystal in differential scanning calorimetry (DSC), which is an index of crystallinity.
    [29] The quinolinone derivative used in the present invention is obtained by coating the water-soluble composition containing the water-soluble polymer again on the particles pulverized in the above-described state. In other words, when the particle size and enthalpy of quinolinone derivatives used in the present invention satisfy the above conditions, the surface of such quinolinone derivatives has high hydrophobicity and the dissolution rate in vivo is not fast enough. By coating the surface with a water-soluble composition containing a water-soluble polymer, the wettability is improved and it can be eluted quickly.
    [30] There is no restriction | limiting in particular as said water-soluble polymer, For example, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose, carboxymethyl cellulose sodium (CMC-Na), hydroxyethyl cellulose, etc. Synthetic polymers such as cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol, and starch derivatives such as pullulan and dextrin, and hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, and carboxymethyl cellulose sodium. And cellulose derivatives such as hydroxyethyl cellulose are preferable, and hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and carboxymethyl cellulose sodium are more preferable.
    [31] These water-soluble polymers may be used by one type, or may mix and use 2 or more types as needed.
    [32] Although the usage-amount of the water-soluble polymer which concerns on this invention is not specifically limited, It is preferable that it is 0.5-12 mass parts with respect to 100 mass parts of quinolinone derivatives, and it is more preferable that it is 1-10 mass parts. Moreover, when mixing two or more of these water-soluble polymers, it is preferable that the total amount of water-soluble polymer is 0.5-12 mass parts with respect to 100 mass parts of quinolinone derivatives, and it is more preferable that it is 1-10 mass parts.
    [33] If the amount of the water-soluble polymer is less than 0.5 parts by mass relative to the quinolinone derivative, the wettability of the quinolinone derivative is not sufficiently improved, and a rapid dissolution rate tends not to be obtained. Although improved, the dissolution time of the coated water-soluble polymer itself tends to be prolonged, so that a rapid dissolution rate of the quinolinone derivative is not obtained.
    [34] It is preferable that the water-soluble composition used by this invention contains surfactant further. Surfactants are used together with the water-soluble polymers described above to coat the surface of the quinolinone derivatives, thereby imparting better in vivo dissolution properties of the quinolinone derivatives.
    [35] As said surfactant, for example, sucrose fatty acid ester, polyoxyethylene hardened castor oil, polyoxyethylene fatty acid ester, polyoxyethylene glycol, polyoxyethylene sorbitan fatty acid ester, alkyl sulfate, alkylbenzene sulfonate, sulfosuccinic acid ester Salts.
    [36] Especially, alkyl sulfate, alkylbenzene sulfonate, and sulfosuccinic acid ester salt which are anionic surfactants are more preferable. Examples of the alkyl sulfate ester salts include sodium lauryl sulfate, and the sulfosuccinic acid ester salts include dioctylsodium sulfosuccinate. One kind of such surfactants may be used, or two or more kinds thereof may be mixed and used as necessary.
    [37] It is preferable that it is 0.1-20 mass parts with respect to 100 mass parts of quinolinone derivatives, and, as for the usage-amount of surfactant, it is more preferable that it is 0.1-10 mass parts. Moreover, when using these surfactant in mixture of 2 or more types, it is preferable that it is 0.1-20 mass parts with respect to 100 mass parts of quinolinone derivatives, and, as for the total amount of surfactant, it is more preferable that it is 0.1-10 mass parts.
    [38] The pharmaceutical composition of the present invention exhibits a sufficiently high dissolution rate even when used as it is, but in order to further promote the dissolution rate, it is preferable to add a disintegrant. Examples of disintegrating agents include starch and derivatives thereof, such as cornstarch, hydroxypropyl starch, carboxymethyl starch sodium, partially alpha starch, carmeloose, carmellose calcium, croscarmellose sodium, and low substitution. Cellulose, such as moderate hydroxypropyl cellulose, and derivatives thereof, and synthetic polymers such as crospovidone. Among them, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carmellose calcium, and carboxy. Sodium methyl starch and crospovidone are preferred. These disintegrating agents may be used by one type, and 2 or more types may be mixed and used as needed.
    [39] It is preferable that it is 1-30 mass parts with respect to 100 mass parts of quinolinone derivatives, and, as for the usage-amount of such a disintegrating agent, it is more preferable that it is 3-20 mass parts. Moreover, when mixing two or more types of these disintegrating agents, it is preferable that it is 1-30 mass parts with respect to 100 mass parts of quinolinone derivatives, and, as for the total amount of a disintegrating agent, it is more preferable that it is 3-20 mass parts.
    [40] The pharmaceutical composition of the present invention obtained by the above method may contain any of the above quinolinone derivatives as an active ingredient, and the specific prescription and formulation thereof are not particularly limited. For example, excipients, disintegrants, binders, lubricants. Pharmaceutical composition having a formulation such as powder, granule, dry syrup, tablet, chewable tablet, toroki tablet, effervescent tablet, capsule, pill, after addition of surfactant, coating agent, antioxidant, flavoring agent and coloring agent What is necessary is just to formulate as. The manufacturing method of these pharmaceutical compositions can employ | adopt the suitable method available to a person skilled in the art according to the form of pharmaceutical composition.
    [41] Examples of the excipient include starch and its derivatives (dextrin, carboxymethyl starch, etc.), cellulose and its derivatives (methyl cellulose, hydroxypropylmethyl cellulose, etc.), sugars (lactose, D-mannitol, glucose, etc.), Silicates and silicates (natural aluminum silicate, magnesium silicate), carbonates (calcium carbonate, magnesium carbonate, sodium hydrogen carbonate, etc.), aluminum hydroxide, magnesium hydroxide, synthetic hydrotalcite, polyoxyethylene derivatives, monostearate glycerine, monoolefin sorbate A shot.
    [42] As the binder, for example, starch and its derivatives (alpha starch, dextrin, etc.), cellulose and its derivatives (ethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, etc.), gum arabic, tragant, Gelatin, sugars (glucose, white sugar, etc.), ethanol, polyvinyl alcohol.
    [43] As the lubricant, for example, stearic acid, hardened oil, calcium stearate, magnesium stearate, talc, silicic acid and salts thereof (light silica anhydride, natural aluminum silicate), titanium oxide, calcium hydrogen phosphate, dry aluminum hydroxide gel, Macrogol can be mentioned.
    [44] As the coating agent, for example, cellulose derivatives (hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate), shellac, polyethylene glycol, polyvinylpyrrolidone, poly Vinylpyridines (poly-2-vinylpyridine, poly-2-vinyl-5-ethylpyridine and the like), polyvinylacetyldiethylaminoacetate, polyvinyl alcohol phthalate, and methacrylate-methacrylic acid copolymer.
    [45] Moreover, as said antioxidant, for example, sulfites (sodium sulfite, sodium bisulfite, etc.), rongalit, erythorbic acid, L-ascorbic acid, cysteine, thioglycerol, butylhydroxy anisol, dibutylhydroxytoluene Propyl gallic acid, ascorbic acid palmitate, and dl-α-tocopherol.
    [46] Moreover, as said fragrance | flavor, dl-menthol, l-menthol, sugar flavor, mint flavor, vanilla flavor, skin oil, peppermint oil, eucalyptus oil, cinnamon oil are mentioned, for example.
    [47] Examples of the colorant include indigocarmine, caramel, riboflavin, edible tar dyes, iron oxides, titanium oxides, β-carotene, chlorophyll, and lake dyes.
    [48] Moreover, although content of the quinolinone derivative represented by said structural formula (I) in the pharmaceutical composition of this invention changes also with the dosage form, 0.01-99.9 mass% is generally preferable.
    [49] Next, the manufacturing method of the quinolinone derivative pharmaceutical composition of this invention is demonstrated.
    [50] First, the 1st process in the manufacturing method of this invention is demonstrated.
    [51] The quinolinone derivatives produced by the method shown in the prior art column are usually particles having an average particle diameter of about 20 to 150 µm. However, it is difficult to elute in vivo as particles having such a particle diameter.
    [52] The apparatus used for the pulverization of the quinolinone derivatives has an average particle diameter of 0.5 to 10 µm and a proportion of particles having a particle diameter of 15 µm or less while maintaining the quinolone derivative particles after the grinding at a high level. What is necessary is just an apparatus which can be grind | pulverized into the particle | grains which have the particle size distribution which occupies the above, For example, an impact mill (hammer mill), a ball mill, a wet mill, and a jet grinder are mentioned, Especially, it is preferable to use a jet grinder. By using a jet grinder, it is possible to grind under relatively mild conditions at the time of grinding of the crystal, which makes it possible to grind while maintaining the enthalpy of melting of crystals at a high level.
    [53] Further, Japanese Patent Laid-Open No. 11-255649 discloses that the absorption of quinolinone derivatives for about 10 minutes using an automatic agate induction improves the bioabsorbability. The crystallinity of the derivative crystals is lowered, and as a result, the enthalpy of fusion is lowered to less than 30 J / g. Therefore, there is a problem that the stability is lowered. can do.
    [54] Next, a second step according to the present invention will be described.
    [55] The method of coating the particles obtained in the first step is not particularly limited as long as a composition is obtained in which all or part of the particle surface of the quinolinone derivative is coated with a water-soluble composition containing a water-soluble polymer. (1) a method in which a solution obtained by dissolving a water-soluble composition containing a water-soluble polymer in water or a suitable organic solvent is mixed with a quinolinone derivative, wet granulated and then dried, and (2) a quinolinone derivative is nucleated. Spray coating a water-soluble composition containing a water-soluble polymer dissolved in water or a suitable organic solvent as a particle; (3) dispersing a quinolinone derivative in a solution of a water-soluble composition containing a water-soluble polymer dissolved in water or a suitable organic solvent. And spray drying. Among these, the method of said (1) is preferable.
    [56] In addition, the dosage of the pharmaceutical composition of the present invention can be appropriately determined according to the severity of symptoms, age, administration method, doctor's diagnosis, and the like, but, for example, the dosage of the quinolinone derivative represented by the above structural formula (I) It is preferable that it is 0.1-200000 mg / kg per 1 kg of body weight per day. The administration of the pharmaceutical composition of the present invention may be administered by combining the above doses once in 1 to 7 days, depending on the severity of the symptoms, the judgment of the doctor, or the like.
    [57] Example
    [58] Hereinafter, although an Example and a comparative example demonstrate this invention more concretely, this invention is not limited to the range of the following Example.
    [59] Hereinafter, when there is no clue in particular, "%" shall represent "mass%."
    [60] (Preparation example)
    [61] According to the method of Example 38 of Unexamined-Japanese-Patent No. 9-255659, 7- (3,5-dimethoxy-4-hydroxycinnamoylamino) -3-octyloxy-4 represented by said structural formula (I) -Hydroxy-1-methyl-2 (lH) -quinolinone (hereinafter referred to simply as a quinolinone derivative) is synthesized, and according to the method described in Reference Example 2 of Japanese Patent Laid-Open No. 11-255649, Quinolone derivatives of β-type were obtained.
    [62] The above method was performed twice to obtain quinolinone before grinding. (Hereinafter referred to as quinolinone derivative (A) and quinolinone derivative (B))
    [63] Particle size distribution of the quinolinone derivative (A) was measured, and differential scanning calorimetry (DCS) was carried out. As a result, the proportion of particles having an average particle diameter of 25.3 µm and a particle diameter of 15 µm or less occupied by all particles was 9.9% and melting enthalpy. (ΔH) was 49.9 J / g.
    [64] The quinolinone derivative (B) was also measured in the same manner. As a result, the proportion of the particles having an average particle diameter of 33.3 µm and 15 µm or less in all the particles was 0.6%, and ΔH was 52.7 J / g.
    [65] Next, the quinolinone derivative (A) and the quinolinone (B) were pulverized with a jet mill (A-0 jet mill: manufactured by Seishin Co., Ltd.) (powder feed rate of about 0.75 g / min, air pressure of 6 to 7 kg /). Cm 2). The pulverized product of the quinolinone derivative thus obtained is referred to as quinolinone (A-1) and quinolinone (B-1), respectively. Particle size distribution of the pulverized product of the obtained quinolinone derivatives was measured, differential scanning calorimetry (DSC) was performed, and the results are shown in Table 1 inclusive.
    [66] <Analysis condition>
    [67] Particle size distribution measurement: The particle size distribution was automatically measured by AEROSIZER (manufactured by Central Chemical Corporation).
    [68] DSC method: DSC7 (made by Perkin Elmer) was used, and it measured by the conventional method in 25-250 degreeC on the conditions of 20 degree-C / min of temperature rising rates.
    [69] TABLE 1
    [70] QuinolinoneAverage particle diameter (Μm)Occupied % Of particles below 15㎛DSC Endothermic peak (℃)DSC Fusion EnthalpyΔH (J / g) (A)25.39.915149.9 (A-1)4.510014747.7 (B)33.30.615052.7 (B-1)6.69514651.6
    [71] As is clear from the results shown in Table 1, the average particle diameter of the pulverized product of the quinolinone derivative was 10 m or less. Moreover, it was confirmed that the ratio of the particle | grains whose particle diameter of a quinolinone derivative is 15 micrometers or less occupies 100%. In addition, from the results of the DSC measurement, the enthalpy of melting of the pulverized product (AH) was not remarkably lower than that of the pulverized product.
    [72] (Example 1 and Comparative Example 1)
    [73] Powder X-ray diffraction was measured for the quinolinone derivative (A) (Comparative Example 1) and the quinolinone derivative (A-1) (Example 1), and the results are shown in FIG. 1.
    [74] In addition, the dissolution properties of these quinolinone derivatives were evaluated by the dissolution test (paddle method), and the results are shown in FIG. 2.
    [75] Powder X-ray diffraction method: Using RINT-ULTIMA (made by Rigaku Denki Co., Ltd.), it measured by the conventional method in the range of 5-40 degrees on the conditions of Cu-K (alpha) ray, 40KV, and 30mA.
    [76] Dissolution test method: According to the dissolution test method method 2 (paddle method) of the 14th revision of the Japanese Pharmacopoeia, 0.5% sodium lauryl sulfate was used for the test liquid, and it measured on 50 conditions of paddles.
    [77] The powder X-ray diffraction patterns of the pulverized product and the pulverized product were consistent with each other as shown in FIG. 1, and both of them maintained β-type crystals. On the other hand, the dissolution rate of the pulverized product was significantly higher than that of the pulverized product as shown in FIG.
    [78] From the above results, it can be seen that by jet-pulverizing the quinolinone derivative, it is refined while suppressing the amorphousness and the elution rate is improved.
    [79] (Comparative Example 2)
    [80] In order to make the particle size 10 micrometers or less, the quinolinone derivative (A) before grinding | pulverization used by the comparative example 1 was grind | pulverized for 30 minutes by agate mortar. As a result of performing DSC measurement on the obtained quinolinone derivative, it was confirmed that the endothermic peak due to the melting of the β-form crystal was lost and was amorphous.
    [81] (Examples 2 to 6 and Comparative Example 3)
    [82] As a water-soluble polymer which coats a quinolinone derivative, hydroxypropyl cellulose (HPC-L: manufactured by Nippon Shoki Co., Ltd., viscosity = 6-10 cps) (Example 2), hydroxypropyl methyl cellulose (HPMC TC-5MW: Synthetic Chemicals Co., Ltd. (Example 3), pullulan (Example 4), carboxymethyl cellulose sodium (CMC-Na: manufactured by Oude Chemical Co., Ltd.) (Example 5), polyvinylpyridolidon (PVP: manufactured by Ohkyo Corp.) (Example 6) was used.
    [83] According to the prescription shown in Table 2, a quinolinone derivative (A-1; pulverized product), lactose (200M DMV), crystalline cellulose (Avisel PH101, manufactured by Chemical Co., Ltd.) and low-substituted hydroxypropyl cellulose (L-HPC LH- 31: Made in Shinju Chemical Co., Ltd. Next, an aqueous solution of various water-soluble polymers dissolved in an appropriate amount of water in advance was added to the composition (10 parts by mass based on the quinolinone derivative 100) and kneaded, and then sieved to a No. 20 sieve and dried. After drying, the particles were sized into a No. 35 sieve to obtain quinolinone derivative particles surface-coated with various water-soluble polymers.
    [84] TABLE 2
    [85] Example 2Example 3Example 4Example 5Example 6Comparative Example 3 Water soluble polymerPHC-LHPMCPullulanCMC-NaPVP--- FurtheranceQuinolinone derivative derivatives1 g1 g1 g1 g1 g1 g Lactose0.5g0.5g0.5g0.55 g.0.5g--- Crystalline cellulose0.2 g0.2 g0.2 g0.2 g0.2 g--- L-HPC (LH-31)0.2 g0.2 g0.2 g0.2 g0.2 g--- HPC-L0.1g--------------- HPMC TC-5MW---0.1g------------ Pullulan------0.1g--------- CMC-Na---------0.05g------ PVP------------0.1g--- system2 g2 g2 g2 g2 g1 g
    [86] The elution property of the obtained granule was evaluated by the elution test (flow through cell method). That is, according to the dissolution test method 3 (flowthrough cell method) of the 14th revision of the Japanese Pharmacopoeia, it measured on the conditions of about 7 ml of flow rates using 1% polysorbate 80 as a test liquid. As a control, the dissolution rate of the pulverized product (Comparative Example 3) of the quinolinone derivative not coated with the water-soluble polymer was also measured.
    [87] The dissolution test results of the pulverized product of the quinolinone derivative surface-coated with each water-soluble polymer and the pulverized product of the quinolinone derivative not surface-coated with the water-soluble polymer are shown in FIG. 3. From the results shown in FIG. 3, the pulverized product of the quinolinone derivative surface-coated with various water-soluble polymers exhibited a higher dissolution rate than the pulverized product of the quinolinone derivative not coated with the water-soluble polymer. It can be seen that it is effective to improve the dissolution rate of the pulverized product of the quinolinone derivative. Moreover, the comparison of various water-soluble polymers shows that the dissolution rate is remarkably improved especially when HPC-L and CMC-Na are used. .
    [88] (Examples 7-11)
    [89] In accordance with the formulation shown in Table 3, quinolinone derivatives (A-l: ground products), lactose, crystalline cellulose and L-HPC were mixed in the mortar. 4 mass parts (Example 7), 6 mass parts (Example 8), 8 mass parts (Example 9), and 10 mass of the aqueous solution of HPC-L previously melt | dissolved with appropriate quantity of water with respect to 100 mass parts of quinolinone derivatives, respectively. After addition and kneading | mixing to the said composition so that it might become a part (Example 10) and 12 mass parts (Example 11), it was made up to 20 sieves, and dried. After drying, it was sized to a No. 35 sieve to obtain quinolinone derivative granules. 0.5% of magnesium stearate was blended into the obtained quinolinone derivative granules, and 200 mg of the blended powder was subjected to static pressure tableting at a pressure of 600 kg by a hydraulic press using an 8 mm-2 stage R pestle ball mortar. Got it.
    [90] TABLE 3
    [91] Example 7Example 8Example 9Example 10Example 11 Hydroxypropyl Cellulose (HPC-L)4%6%8%10%12% FurtheranceQuinolinone derivative derivatives2.0 g2.0 g2.0 g2.0 g2.0 g Lactose1.12 g1.08g1.04 g1.00 g0.96 g Crystalline cellulose0.4g0.4g0.4g0.4g0.4g L-HPC (LH-31)0.4g0.4g0.4g0.4g0.4g HPC-L0.08g0.12 g0.16 g0.2 g0.24 g system4.0g4.0g4.0g4.0g4.0g
    [92] The disintegration time of the tablets thus obtained was measured by using water in the test solution in accordance with the disintegration test method of the JP 14th amendment (n = 3). The result of the disintegration test of the obtained tablet is shown in FIG. The dissolution test was conducted under conditions of 50 revolutions of the paddle using 0.5% sodium lauryl sulfate in the test solution according to the Dissolution Test Method No. 2 (paddle method) of the Japanese Pharmacopoeia 14th Amendment. The result of the dissolution test of the obtained tablet is shown in FIG.
    [93] The results shown in FIG. 4 show that relatively fast disintegration (within 30 minutes) is obtained when the amount of HPC-L added is 10% by mass or less. As a result shown in FIG. 5, it can be seen that relatively fast elution (elution rate of 75% or more in 60 minutes) is obtained as the amount of HPC-L addition amount of 10% by mass or less.
    [94] (Examples 12-18)
    [95] According to the prescription shown in Table 4, quinolinone derivatives (A-1; pulverized products), lactose, crystalline cellulose (avicel PH11) and various disintegrating agents were mixed in the mortar. The disintegrating agent used was a low-substituted hydroxypropyl cellulose (L-HPC LH-31: manufactured by Shinsei Chemical Co., Ltd.) (Example 12), croscarmellose sodium (Ac-Di-Sol: manufactured by Kasei Chemical Co., Ltd.) (Example 13) , Carmeloose (NS-300: manufactured by Odetsu Co., Ltd.) (Example 14), Carmeloose calcium (ECG-505: made by Odedo Co., Ltd.) (Example 15), partially alpha starch (PCS: 旭 化成) Manufactured by Example) (Example l6), carboxymethyl starch sodium (primogel: manufactured by Matsumoto Chemical Co., Ltd.) (Example 17), and crospovidone (Collidon CL: manufactured by BASF Corporation) (Example 18). It mixed so that it may become 20 mass% with respect to a quinolinone derivative.
    [96] Next, an aqueous solution of HPC-L dissolved in an appropriate amount of water in advance was added to the composition and kneaded so as to be the amount shown in Table 4, and then sieved to No. 20 sieve and dried. After drying, the particles were sized in a No. 35 sieve to obtain quinolinone derivative granules. Magnesium stearate was mix | blended with the obtained granule 0.5%, 200 mg of compounding powders were made into the tablets by static pressure tableting at the pressure of 600 kg using the 8 mm-2 stage R diameter pestle mortar, and by the hydraulic press.
    [97] TABLE 4
    [98] Example 12Example 13Example 14Example 15Example 16Example 17Example 18 DisintegrantL-HPCAc-Di-SolNS-300ECG-505PCSPrimogelCollidone CL FurtheranceQuinolinone derivative derivatives1.5 g1.51.51.5 g1.5 g1.5 g1.5 g Lactose0.7650.7650.7650.7650.7650.7650.765 Crystalline cellulose0.30.30.30.30.30.30.3 HPC-L0.1350.1350.1350.1350.1350.1350.135 L-HPC (LH-31)0.3------------------ Ac-Di-Sol---0.3--------------- NS-300------0.3 g------------ ECG-505---------0.3 g--------- PCS------------0.3 g------ Primogel---------------0.3 g--- Collidone CL------------------0.3 g system3.0 g3.0 g3.0 g3.0 g3.0 g3.0 g3.0 g
    [99] The disintegration time of the tablets thus obtained was measured by using water in the test solution in accordance with the disintegration test method of Japanese Patent Application No. 14 (n = 3). The result of the disintegration test of the obtained tablet is shown in FIG. Moreover, the dissolution test was done about the refinement | purification with favorable dispersibility at the time of a collapse test. The dissolution test was carried out under the conditions of 50 revolutions of the paddle using 0.5% sodium lauryl sulfate in the test solution according to the Dissolution Test Method No. 2 (paddle method) of the 14th Japanese Pharmacopoeia. The dissolution test results of tablets using L-HPC, Ac-Di-So1, ECG-505, primogel, and collidone CL having good dispersibility are shown in FIG. 7.
    [100] From the results shown in FIG. 6, it can be seen that rapid disintegration (within 30 minutes) is obtained in all of the disintegrating agents used. In PCS and NS-300, however, the dispersed particles at the time of collapse were rough and poor in dispersibility. In addition, from the results shown in Fig. 7, fast dissolution property (elution rate of 75% or more in 60 minutes) was shown even when any disintegrating agent was used, and in particular, rapid dissolution in Ac-Di-Sol, collidone CL, and ECG-505. It can be seen that speed is obtained.
    [101] (Examples 19 to 21)
    [102] According to the prescription shown in Table 5, a quinolinone derivative (A-1; pulverized product), lactose, crystalline cellulose and Ac-Di-So1 were mixed with a vertical granulator (VG-01 manufactured by Faurek Co., Ltd.). Said Ac-Di-So1 was prepared by three types which prepared final density | concentration in 10 mass% (Example 19), 15 mass% (Example 20), and 20 mass% (Example 21). An aqueous solution of HPC-L dissolved in an appropriate amount of water in advance was added to the composition and kneaded so as to be the amount shown in Table 5, and then sieved and vacuum-dried by a speed mill (ND-10: manufactured by Takada Seiko Co., Ltd.). After drying, it was sized to No. 20 sieve to obtain quinolinone derivative granules. 0.5% magnesium stearate was blended into the granules of the obtained quinolinone derivatives, and 200 mg of the blended powder was tableted at a pressure of 600 kg using a single tableting machine (N-20: manufactured by Takada Seiko Co., Ltd.) using a pestle ball of 8 mm-10 R in diameter. A tablet was obtained.
    [103] TABLE 5
    [104] Example 19Example 20Example 21 Ac-Di-Sol10%15%20% FurtheranceQuinolinone derivative derivatives150 g150 g150 g Lactose91.5 g84 g76.5 g Crystalline cellulose30 g30 g30 g HPC-L13.5 g13.5 g13.5 g Ac-Di-Sol15 g22.5 g30 g system300 g300 g300 g
    [105] The disintegration time of the tablets thus obtained was measured by using water in the test solution in accordance with the disintegration test method of Japanese Patent Application No. 14 (n = 3). Table 6 shows the results of the disintegration test of the obtained tablet. The dissolution test was conducted under conditions of 50 revolutions of the paddle using 0.5% sodium lauryl sulfate in the test solution according to the Dissolution Test Method No. 2 (paddle method) of the Japanese Pharmacopoeia 14th Amendment. The dissolution test result of the obtained tablet is shown in FIG.
    [106] TABLE 6
    [107] Sample (Ac-Di-Sol)Decay time Example 1910%8.6 minutes Example 2015%8.0 minutes Example 2120%7.1 minutes
    [108] From the result shown in Table 6, it turns out that fast disintegration (within 30 minutes) is shown in the range of 10-20 mass% of Ac-Di-Sol addition amounts. Moreover, from the result shown in FIG. 8, it turns out that fast elution property (elution rate 75% or more in 60 minutes) is obtained in the range of 10-20 mass% of Ac-Di-So1 addition amounts.
    [109] (Example 22 and Comparative Examples 4-5)
    [110] Nine eagle dogs (male, 12 months old) fasted day and night, quinolinone derivatives (B; pulverized products) (Comparative Example 4) and quinolinone derivatives (B-1) filled in capsule No. 1 Pulverized product) (Comparative Example 5) and HPC granules of quinolinone derivatives prepared in Example 2 (Example 22) were orally administered as a quinolinone derivative at a dose of 10 mg / kg. In addition, 30 ml of distilled water was orally added after administration. After administration, 2.5 ml of blood was collected from the forearm vein over time, and serum was obtained by centrifugation. After removing the protein by adding acetonitrile in doubling to the serum, the quinolinone derivative and its metabolite were quantified using HPLC.
    [111] From the quantitative values of the quinolinone derivatives and their metabolites at the time of blood collection, the mean value of the highest blood concentration (C max ) and the mean value of the blood concentration time curve area (AUC) were determined. The results are shown in Table 7. From the results shown in Table 7, the pulverized product of the quinolinone derivative was found to have a C max of 9 times and an AUC of 8.7 times that of the pulverized product, and a tendency to improve water absorption by pulverization was confirmed. Further, HPC granules of the quinolinone derivative is increased as compared with the milling product, C max is 16.5-fold, fold AUC is 13.3, even compared to the pulverized product, C max is 1.8 times, AUC is increased to 1.5 times, HPC It can be seen that the effect of the surface coating of the quinolinone derivatives is recognized. From the above results, it can be seen that the surface coating with the pulverized and water-soluble polymer improves the digestive tract absorption. In Table 7, ** indicates that the result of the t test was p <0.01.
    [112] TABLE 7
    [113] sampleCmax (ng / ml)AUC (nghr / ml) Example 19Quinolinone derivative fine grinding152.3872.0 Example 20Quinolinone derivatives1364.67580.5 Example 21HPC-L Coated Particles2516.9 **11605.5 **
    [114] (Example 23 and Comparative Example 6)
    [115] According to the prescription shown in Table 8, quinolinone derivative (B; finely divided product) (Comparative Example 6), or quinolinone derivative (B-1; ground product) (Example 23), lactose, crystalline cellulose, Ac Mixed Di-So1 in the trigger. Separately, an aqueous solution of HPC-L dissolved in an appropriate amount of water was added to the composition and kneaded to the amount shown in Table 8, and then sieved and dried in a No. 20 sieve. After drying, the mixture was granulated in a No. 35 sieve to obtain granules using a quinolinone derivative finely ground product and a ground product.
    [116] TABLE 8
    [117] Comparative Example 6Example 23Quinolinone derivative derivativesQuinolinone derivative derivatives FurtheranceQuinolinone derivative derivatives5 g----- Quinolinone derivative derivatives-----5 g Lactose3.05 g3.05 g Avicel PH1011 g1 g HPC-L0.45 g0.45 g Ac-Di-Sol0.5g0.5g system10 g10 g
    [118] 9 non-eagle dogs (males, 12 months old) fasted day and night, granules and quinolinone derivatives (B-1; pulverized) using quinolinone derivatives (B; pulverized products) filled in capsule 1 Granules) were orally administered at a dose of 10 mg / kg as a quinolinone derivative. In addition, 30 ml of distilled water was orally added after administration. After administration, 2.5 ml of blood was collected from the forearm vein over time, and serum was obtained by centrifugation. After removing the protein by adding acetonitrile in doubling to the serum, the quinolinone derivative and its metabolite were quantified using HPLC.
    [119] From the quantitative values of the quinolinone derivatives and their metabolites at the time of blood collection, the mean value of the highest blood concentration (C max ) and the mean value of the blood concentration time curve area (AUC) were determined. The results are shown in Table 9. From the results shown in Table 9, it can be seen that the granules using the pulverized product of the quinolinone derivatives increased the C max by 3.9 times and the AUC by 4.3 times as compared with the granules using the finely ground product, and the effect of improving water absorption was confirmed. . From these results, it was shown that control of the particle size in the formulation is an important factor for improving the absorbency. In Table 9, * indicates that the result of the t test was p <0.05.
    [120] TABLE 9
    [121] sampleCmax (ng / ml)AUC (ng · hr / ml) Comparative Example 6Fine Grinding Particles331.22021.3 Example 23Crushed Particles1289.1 *8620.2 *
    [122] (Examples 24 to 26)
    [123] According to the prescription shown in Table 10, quinolinone derivatives (B-1; pulverized products), lactose, crystalline cellulose (Avisel PH101), Ac-Di-So1 and various surfactants were mixed in the mortar. As the surfactant, dioctylsodium sulfosuccinate (manufactured by Aldrich) (Example 24) and sodium lauryl sulfate (manufactured by Tokyo Chemical Corporation) (Example 25) were used. Moreover, surfactant addition (Example 26) was also prepared. An aqueous solution of HPC (Viscosity = 3 to 5.9 cps, dissolved in appropriate amounts of water) in these compositions was added and kneaded to the amount shown in Table 10, followed by drying and granulation to granulate quinolinone derivatives. Got. Magnesium stearate was mix | blended with the obtained granule, 200 mg of compounding powders were subjected to static pressure tableting at the pressure of 600 kg by the hydraulic press using the 8 mm diameter ball ball mortar, and the tablet was obtained.
    [124] TABLE 10
    [125] Example 24Example 25Example 26 FurtheranceQuinolinone derivative crushed product50.0%50.0%50.0% Lactose29.9%25.0%30.0% Avicel PH10110.0%10.0%10.0% Ac-Di-Sol5.0%5.0%5.0% Dioctyl Sodium Sulfosuccinate0.1%-- Sodium Lauryl Sulfate-5.0%- HPC4.5%4.5%4.5% Magnesium stearate0.5%0.5%0.5%
    [126] The elution of the obtained tablet was carried out under the conditions of 100 revolutions of the paddle using 0.2% sodium lauryl sulfate in the test solution according to the elution test method 2 (paddle method) of the 14th Japanese Pharmacopoeia. The results are shown in FIG.
    [127] From the results shown in FIG. 9, the tablet coated with the water-soluble polymer and the surfactant showed a more preferable dissolution rate than the tablet coated with the water-soluble polymer only, and the surface coating with the water-soluble polymer and the surfactant showed the It can be seen that it is effective to improve the dissolution rate.
    [128] (Example 27 and Example 28)
    [129] According to the prescription shown in Table 11, a quinolinone derivative (B-1; pulverized product), dioctylsodium sulfosuccinate, Ac-Di-Sol, lactose, crystalline cellulose and L-ascorbic acid were mixed in the mortar. . An aqueous solution of HPC dissolved in an appropriate amount of water in this composition was added to the composition so as to be shown in Table 11, kneaded, dried, and granulated to obtain quinolinone derivative granules. After mix | blending magnesium stearate with the obtained granules, 200 mg of compounding powders were compressed into tablets at a tablet pressure of 200 kg using an 8 mm-10 R diameter fine ball mortar, to obtain a tablet (Example 27).
    [130] A quinolinone derivative (B-1; pulverized product), Ac-Di-Sol, lactose, crystalline cellulose, and L-ascorbic acid were mixed in a mortar. In this composition, an aqueous solution of HPC-L dissolved in an appropriate amount of water was added to the composition so as to be shown in Table 11, kneaded, dried, and granulated to obtain quinolinone derivative granules (Example 28).
    [131] TABLE 11
    [132] Example 27Example 28 FurtheranceQuinolinone derivative crushed product50.0%50.0% Lactose29.7%30.0% Avicel PH10110.0%10.0% Ac-Di-Sol5.0%5.0% Dioctyl Sodium Sulfosuccinate0.3%- HPC4.5%4.5% Magnesium stearate0.5%0.5%
    [133] Six rhesus macaques (male, body weight: around 5 to 6 kg) that were purified for one week were orally administered at a dose of 200 mg / ml as quinolinone derivatives in the form of capsules or tablets. In addition, 50 m1 of distilled water was orally added after administration. After administration, 2.0 ml of blood was collected from the femoral vein over time, and plasma was obtained by centrifugation. After removing a protein by adding acetonitrile to plasma, the quinolinone derivative and its metabolite were quantified using HPLC.
    [134] From the quantitative values of the quinolinone derivatives and their metabolites at the time of blood collection, the mean value of the highest blood concentration (C max ) and the mean value of the blood concentration time curve area (AUC) were determined. The results are shown in Table 12. From the results shown in Table 12, the tablets coated with the water-soluble polymer and surfactant with the pulverized product of the quinolinone derivatives had a C max of 2.3 times compared to the tablets coated with the water-soluble polymer with the quinolinone derivatives, and the AUC was It is 2.1 times or more, and it turns out that it has the further water absorption improvement effect. From this result, it turns out that it is more preferable to coat a quinolinone derivative particle with a water-soluble polymer and surfactant for improving water absorption. In Table 12, * indicates that the result of the t test was p <0.05.
    [135] TABLE 12
    [136] Cmax (ng / ml)AUC (ng · hr / ml) Example 28218531631 Example 275151 *68906 *
    [137] According to the present invention, there is provided a quinolinone derivative pharmaceutical composition capable of rapidly eluting an active ingredient in the digestive tract and excellent in storage stability, and a method for producing the same.
    权利要求:
    Claims (9)
    [1" claim-type="Currently amended] Structural Formula (I)

    A pharmaceutical composition containing a quinolinone derivative represented by the above, wherein the quinolinone derivative has an average particle diameter of 0.5 to 10 µm and a particle size distribution in which a proportion of particles having a particle diameter of 15 µm or less occupies 90% or more, Furthermore, a quinolone derivative pharmaceutical composition, wherein the enthalpy of fusion is 3OJ / g or more and the surface of the particle is covered with a water-soluble composition containing a water-soluble polymer.
    [2" claim-type="Currently amended] The method of claim 1,
    A quinolinone derivative pharmaceutical composition wherein the water-soluble polymer is a cellulose derivative.
    [3" claim-type="Currently amended] The method of claim 1,
    A quinolinone derivative pharmaceutical composition wherein the water-soluble composition contains a water-soluble polymer and a surfactant.
    [4" claim-type="Currently amended] The method of claim 3,
    Quinolinone derivative pharmaceutical composition whose said surfactant is an anionic surfactant.
    [5" claim-type="Currently amended] The method according to any one of claims 1 to 4,
    A quinolinone derivative pharmaceutical composition wherein said quinolinone derivative pharmaceutical composition further comprises a disintegrant.
    [6" claim-type="Currently amended] The method of claim 5,
    The disintegrating agent is at least one quinolinone derivative pharmaceutical composition selected from the group consisting of croscarmellose sodium, low-substituted hydroxypropyl cellulose, carmellose calcium, carboxymethyl starch sodium and crospovidone.
    [7" claim-type="Currently amended] Structural Formula (I)

    The quinolinone derivative represented by is crushed into particles having an average particle diameter of 0.5 to 10 µm, a particle size distribution in which the proportion of particles having a particle diameter of 15 µm or less accounts for 90% or more, and a enthalpy of fusion of 30 J / g or more. The first process, and
    2nd process which coat | covers the particle | grains obtained at the said 1st process with the water-soluble composition containing a water-soluble polymer.
    Method for producing a quinolinone derivative pharmaceutical composition characterized by having
    [8" claim-type="Currently amended] The method of claim 7, wherein
    A method for producing a quinolinone derivative pharmaceutical composition, wherein the grinding is by jet grinding.
    [9" claim-type="Currently amended] The method of claim 7, wherein
    A method for producing a quinolinone derivative pharmaceutical composition wherein the water-soluble composition contains a water-soluble polymer and a surfactant.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10695367B2|2020-06-30|Pharmaceutical compositions
    JP5693635B2|2015-04-01|Orally disintegrating tablet masking bitterness and method for producing the same
    JP3180350B2|2001-06-25|β-lactam antibiotic-containing tablet and method for producing the same
    US7189415B2|2007-03-13|Rapidly disintegrable pharmaceutical composition
    DE60224096T2|2008-04-17|Two-phase pharmaceutical tablet containing telmisartan and hydrochlorothiazide
    CN100563658C|2009-12-02|The solid dispersion of phenylalanine derivative or solid dispersion pharmaceutical preparation
    EP1793824B1|2015-11-18|New pharmaceutical compositions comprising 4-|-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
    EP0701436B1|2003-01-15|Process
    KR101107508B1|2012-01-31|Solid pharmaceutical formulations comprising telmisartan
    CA2092287C|1997-03-25|Controlled release verapamil tablet
    JP5557169B2|2014-07-23|Nateglinide-containing preparation
    EP1830855B1|2010-02-24|Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
    US6844008B2|2005-01-18|Tablet composition
    EP0074584B1|1985-08-21|Prolonged-action multiple-layer tablets
    TWI263507B|2006-10-11|Cilostazol preparation
    TWI482641B|2015-05-01|Pharmaceutical composition containing low substituted hydroxypropylcellulose
    EP1334720B1|2008-09-03|Nateglinide-containing preparations
    US4404183A|1983-09-13|Sustained release pharmaceutical composition of solid medical material
    US6764997B2|2004-07-20|Stabilized azithromycin compositions
    EP1341527B1|2011-08-10|Pharmaceutical preparation comprising an active dispersed on a matrix
    US6936274B2|2005-08-30|Storage stable thyroxine active drug formulations and methods for their production
    JP4098620B2|2008-06-11|Novel pharmaceutical composition and method for preparing the same
    CN100379407C|2008-04-09|Process for manufacturing bite-dispersion tablets
    KR100331529B1|2002-04-06|Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof
    EP2442799B1|2016-09-07|Solid pharmaceutical composition comprising rivaroxaban
    同族专利:
    公开号 | 公开日
    TWI299994B|2008-08-21|
    AT258794T|2004-02-15|
    KR100908418B1|2009-07-21|
    EP1270006B1|2004-02-04|
    CN1214791C|2005-08-17|
    ES2211844T3|2004-07-16|
    US20030130310A1|2003-07-10|
    DE60200202T2|2004-12-30|
    US7081256B2|2006-07-25|
    CA2390746A1|2002-12-20|
    CN1391896A|2003-01-22|
    CA2390746C|2008-02-05|
    AU778764B2|2004-12-23|
    AU4883502A|2003-01-02|
    DE60200202D1|2004-03-11|
    EP1270006A2|2003-01-02|
    EP1270006A3|2003-02-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-06-20|Priority to JP2001187138
    2001-06-20|Priority to JPJP-P-2001-00187138
    2002-06-07|Application filed by 다이니혼 잉키 가가쿠 고교 가부시키가이샤
    2002-12-31|Publication of KR20020096891A
    2009-07-21|Application granted
    2009-07-21|Publication of KR100908418B1
    优先权:
    申请号 | 申请日 | 专利标题
    JP2001187138|2001-06-20|
    JPJP-P-2001-00187138|2001-06-20|
    [返回顶部]